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Abstract
Histone methylation regulates normal stem cell fate decisions through a coordinated interplay between histone
methyltransferases and demethylases at lineage specific genes. Malignant transformation is associated with aberrant
accumulation of repressive histone modifications, such as polycomb mediated histone 3 lysine 27 (H3K27me3) resulting in
a histone methylation mediated block to differentiation. The relevance, however, of histone demethylases in cancer remains
less clear. We report that JMJD3, a H3K27me3 demethylase, is induced during differentiation of glioblastoma stem cells
(GSCs), where it promotes a differentiation-like phenotype via chromatin dependent (INK4A/ARF locus activation) and
chromatin independent (nuclear p53 protein stabilization) mechanisms. Our findings indicate that deregulation of JMJD3
may contribute to gliomagenesis via inhibition of the p53 pathway resulting in a block to terminal differentiation.
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previously shown to inhibit astrocytic differentiation [11]. Altogether, these results suggest that a coordinated temporal interplay
between EZH2 and JMJD3 modulate stem cell self-renewal and
lineage specific gene expression of NSCs.
It was been demonstrated that primary human glioblastomas
have stem-like cells, termed glioblastoma stem cells (GSCs), that
can be enriched for using the neural stem cell marker CD133 and
CD15 [12,13]. GSCs isolated from primary glioblastoma patient
samples maintain the genotype and phenotype of the original
tumour sample from which they were derived [14,15]. GSCs also
maintained genomic stability for up to 35 passages in vitro when
they are cultured in neural stem cell media containing epidermal
growth factor (EGF) and fibroblast growth factor (FGF). Culturing
GSCs in serum containing media such as standard immortalized
glioma cell line media (DMEM with 10% foetal bovine serum),
however, results in genomic instability, aneuploidy and significantly different gene expression profiles compared to the parental
glioblastoma tumors from which they were derived [14].
Furthermore, GSCs more accurately recapitulate clinical aspects
of human glioblastomas such as white matter migration/invasion,
vascular proliferation, necrosis and cellular heterogeneity, features

Introduction
Recent evidence suggests that histone methylation is a dynamic
process that modulates transcriptional activity in both normal and
cancer cells[1–6]. Histone methylation is a result of a coordinated
interplay between histone methyltransferases and demethylases at
lineage specific gene promoters thereby contributing to normal
development by regulating cell fate decisions [4,7]. The relevance
of the interplay between histone methyltransferases and demethylases during differentiation has been demonstrated in the developing central nervous system [8,9]. Here, it was shown that
polycomb protein deletion in embryonic neural stem cells (NSCs)
accelerates either neurogenesis or gliogenesis depending on the
polycomb component deleted and timing of deletion [8–10].
Moreover, others showed that the H3K27 demethylase JMJD3 is
required for re-activation of neuronal specific genes during
differentiation of embryonic NSCs [4]. In these experiments it
was shown that the retinoic acid co-repressor NCOR-2 suppresses
JMJD3 expression. Retinoic acid treatment destabilizes nuclear
NCOR-2 resulting in de-repression of the JMJD3 promoter and
JMJD3 mediated induction of neurogenic differentiation. Moreover, NCOR-2 mediated transcriptional suppression was also
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Fold change is represented as 22DDCt. All experiments were done
in triplicates. Error bars represent means 6SD.

that are absent in immortalized glioma cell lines such as U87 and
U251 [14]. Therefore, GSCs are a more representative model of
the actual patient disease compared to the long established
immortalized glioma cell lines.
In astrocytes, malignant transformation is associated with
aberrant accumulation of repressive histone modifications, such
as tri-methylated histone 3 lysine 27 (H3K27me3) mediated by
histone methyltransferases such as EZH2, resulting in a histone
methylation mediated block to differentiation [1,16]. The
relevance, however, of histone demethylases in cancer remains
less clear. We report that JMJD3, a H3K27me3 specific
demethylase, is induced during differentiation of patient-derived
glioblastoma stem cells (GSCs), where it promotes a differentiationlike phenotype via a chromatin dependent (INK4A/ARF locus
activation) and chromatin independent (direct p53 protein
stabilization) mechanism resulting in a p53-mediated cell cycle
arrest and differentiation. We demonstrate that a subset of GBMs
have somatic mutations of JMJD3 or down regulation of its
mRNA expression secondary to DNA hypermethylation of an
intragenic regulatory element. JMJD3 re-activation via regulatory
element demethylation results in p53-mediated differentiation of
GSCs and suppression of tumorgenicity. Our findings demonstrate
a tumor suppressor function for a histone demethylase and
indicate that deregulation of JMJD3 either through somatic
mutations, epigenetic repression of its mRNA expression or
NCoR2 mediated repression may contribute to human gliomagenesis via inhibition of the p53 pathway resulting in a block to
terminal differentiation.

JMJD3 Functional Studies
For transient JMJD3 overexpression, 4E6 GSCs were nucleofected with 4 mg of empty p3xFLAG-CMV expression vector
(Sigma), p3xFLAG-CMV-JMJD3 wild-type (JMJD3) or
p3xFLAG-CMV-JMJD3 mutant (JMJD3 MT) using the mouse
neural stem cell nucleofector kit by Amaxa (VPG-1004) according
to manufacturer’s protocol. Lipofectamine 2000 (Invitrogen
11668-019) was used to transfect HEK 293 cells according to
manufacturer’s protocol. Briefly, 7E5 cells were seeded in 6-well
plates and allowed to adhere overnight. Transfections were done
at a ratio of 1 mg DNA: 3 ml Lipofectamine 2000 per well. RNA
and protein were isolated at 48 hr and 72 hr respectively. For
siRNA knockdown, 200 nM JMJD3 ON-TARGETplus SMARTpool
(Dharmafect L-023013-01) was transfected into GSCs using
Dharmafect Duo transfection reagent (Dharmafect T-2010). For
5-Azacytidine (5-Aza; Sigma EA2385) treatment following JMJD3
siRNA transfection, JMJD3 siRNA were transfected twice within
a 48 hr period, followed by 5-Aza (5 mM) treatment for 4 days.

Luciferase Reporter Assay
The human GFAP promoter luciferase was from Albee Messing
[17]. The episomal human p21 promoter luciferase reporter
_ENREF_41was from addgene (Plasmid 16451) courtesy of Bert
Vogelstein [18]. A p53 binding site mutant p21 promoter
luciferase reporter was generated by site directed mutagenesis
using QuickChange XL site directed mutagenesis kit (Stratagene
200516) with the following primers: 59-TTT CTG GCC GTC AGG
AAA ATC TCC CAA GAT TTT G-39 and 59-CAA AAT CTT GGG
AGA TTT TCC TGA CGG CCA GAA A-39 targeting the distal 59
TP53 binding site targeting a site previously described to be critical
for p53 activation of the p21 promoter [19]. Transfections were
done with 1 mg of JMJD3 expression construct, 1 mg of luciferase
constructs and 100 ng of Renilla firefly luciferase construct pRLTK (Promega E2241) for background normalization. Cells were
lysed at 24–48 hr for luciferase assay using the promega dual
luciferase reporter system (E1910) according to the manufacturer’s
protocol. All experiments were done in triplicates. Error bars
represent means 6SD.

Methods
Differentiation of Glioblastoma Stem Cells (GSCs)
After written consent tumor samples were obtained from
patients undergoing surgery at the National Institutes of Health
(NIH) in accordance with the surgical procedures of the National
Cancer Institute’s Institutional Review Board that specifically
approved this study. Tissue samples were enzymatically dissociated
and cultured as previously described. 6- well plates were coated
with poly-ornithine (Sigma P4957) for 1 hr at 37uC and washed 3
times with PBS. Cells were plated at 5E5 cells per well (6-well
plate) and treated with 2 mM all trans-retinoic acid, RA (Sigma
R2625) for 5 days. Media was changed approximately every 2–3
days to maintain a constant dose of RA. On day 5, RNA was
collected using Qiagen RNeasy Kit (74106). Cells were lysed
directly on the 6-well plates and total RNA was isolated following
the manufacturers protocol. All experiments were done in
triplicates. Error bars represent means 6SD.

Nuclear Fractionation, Western Blotting and
Immunocytochemistry
Nuclear fractionation was performed in HEK 293 cells (ATCC)
and GSC 923 (Glioblastoma primary cell line derived from patient
sample following the approval of National Cancer Institute
Institutional Review Board) with the Proteoextract subcellular
proteome extraction kit (Calbiochem 539790) according to the
manufacturer’s protocol. For western analysis, 15–30 mg of protein
lysate were run on a bis-tris 4–12% gradient gel (Invitrogen).
Primary anti-bodies used were as follows: mouse anti-human p53
IC12 (Cell Signaling 2524) 1:1000, mouse anti-Flag (Sigma F3165)
10 mg/ml, mouse anti-human p21 WAF/CIP1 12D1 (Cell
Signaling 2947S) 1:1000, rabbit anti-human GFAP (Dako
M0761) 1:4000, rabbit anti-human histone 3 (Millipore 04–928)
1:250, mouse anti-human tubulin (Sigma T3526) 1:5000, For
immunocytochemistry, mouse anti-Flag-FITC Conjugated (Sigma
F4049) 10 mg/ml, rabbit anti-human H3K27me3 (Millipore 07–
449) 1:500, monoclonal mouse anti-b-tubulin III 1:1000 (Covance
MMS-435P), polyclonal rabbit anti-b-tubulin III 1:1000 (Convance PRB-435P) and rabbit anti-human GFAP (Dako M0761)
1:4000.

Quantitative Real Time PCR (RT-qPCR)
500 ng of high-quality RNA from the RA treatments was
reversed transcribed using the applied biosystems taqman reverse
transcription reagents (N8080234) according to manufacturer’s
protocol. RT-qPCR was performed using reagents from applied
biosystems taqman universal PCR mix (4304437) and 20 nM of
FAM- tagged gene specific primers on the 7900HT real time PCR
system. Primers from applied biosystems were as follows: human
p16/p14 (Primers span INK4A and ARF shared Exon 2-Exon 3;
Hs00923894_m1), human and mouse GFAP (Hs 00909236_m1,
Mm01253033_m1), human p21 (Hs 00355782_m1), human and
mouse JMJD3 (Primers span Exon1-Exon2; Hs 00389738_m1,
Mm 01332680_m1), human TP53 (Hs00153349_m1). Relative
gene expression was determined from the difference in Ct values
between specific genes and endogenous GAPDH control (DCt).
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Co-immunoprecipitation (Co-IP)

DNA Methylation Microarray

Immunoprecipitations were performed in HEK 293 cells and
GSC 923 according to the Santa Cruz Exacta-Cruz protocol (sc450420 and sc-45056). Briefly, 500–1000 mg of protein lysate was
incubated with mouse anti-IgG negative control ICO-97 (Santa
Cruz sc 66186) 1:50, mouse anti-Flag (Sigma F3165) 10 mg/ml
and mouse anti-p53 IC12 (Cell Signaling 2524) 1:500 or mouse
anti-p53 DO1 (Santa Cruz sc-126). IP samples were analyzed on
a bis-tris 4–12% gradient gel (Invitrogen) following Santa Cruz
Exacta-Cruz protocol.

DNA from fresh frozen GBM tumor specimens were used for
hybridization on Infinium Human Methylation 450 BeadChip,
following the Illumina Infinium HD Methylation protocol and
published methods [22]. Annotation of the human JMJD3 locus
The UCSC human genome browser NCBI36/Hg18. Release date
March 2006 (http://genome.ucsc.edu/).

Methylation Specific Sequencing
Methylation analysis of the intragenic regulatory area of JMJD3
was performed on genomic DNA extracted from GSC 827 treated
5 mm 5-Azacytidine for 4 days and from untreated control GSC
827. Bisulfite conversion of DNA samples was performed using
EpiTect Bisulfite Kit (Qiagen), following manufacturer’s instructions. For amplification of the CpG islands, the following primers
where
used:
39JMJD3_F:TTTGTTTTTTATTAATTTGTGTTTTT
39
JMJD3_R:
TCCTACAACTAAAACTTCCACCTAC. PCR products where then subcloned
using the TOPO TA Cloning Kit (Invitrogen, Carlsbad, CA)
following manufacturer’s instructions. PCR verified 24–32 clones
where then sequenced using the vectors T3 priming sites.

Chromatin Immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed according to
SABiosciences Champion CHIP-PCR manufacturer’s protocol
(SABioscience 334471). Briefly HEK 293 cells grown in DMEM
with 10% fetal bovine serum were transfected with either empty
vector or JMJD3 using Lipofectamine 2000 (Invitrogen). Cells
were cross-linked with 1% formaldehyde and the extracts were
enzymatically digested as previously described [20]. Cross-linked
material was immunoprecipitated with 4 mg of antibodies overnight at 4uC and followed by incubation with protein A beads
(SABiosciences) for 1 hr at 4uC. After several washes, the
complexes were eluted and the cross-linking was reversed
according to SABiosciences protocol. Immunoprecipitated DNA
was recovered by DNA extraction beads (SABiosciences) and
analyzed by SYBR green real-time PCR. DCt values were
determined by [Ct (target protein)- Ct (IgG negative control)].
Fold changes are represented as 22DDCt. The primers used were
from SABioscience and corresponded to the p21 transcription start
sites (TSS), 1Kb upstream of TSS (21Kb) and the region
corresponding to the distal p53 binding site (22 to 23Kb).

JMJD3 Locus Annotation
JMJD3 genomic annotation was done using the The UCSC
human genome browser NCB136/Hg18 at (www.genome.ucsc.
edu). The JMJD3 regulatory domain was annotated using Open
Regulatory Annotation Consortium (www.oreganno.org/
oregano).

Intracranial Tumor Cell Injection into SCID Mice
A plasmid, hg01508s1, containing the human JMJD3 cDNA
(KIAA0346) was obtained from the cDNA bank section of Kazusa
DNA Research Institute, Japan. The JMJD3 open reading frame
(ORF) was PCR-amplified and cloned into a pLenti4/TO/V5DEST Gateway vector (Invitrogen). Viruses were generated and
purified using Invitrogen’s viraPower lentiviral expression system.
An intracranial orthotropic model was utilized for evaluation of
gliobastoma stem cell tumorgenicity as previously described [20].
Briefly, empty vector and JMJD3 infected GSC 827 were
dissociated and resuspended in 2 ml of HBSS. 1E5 GSCs, as
determined by trypan blue dye exclusion, were injected stereotactically into the lateral ventricles of neonatal SCID mice. This
study was carried out in strict accordance with the
recommendations from the National Cancer Institute Animal
Care and Use Committee who approved the study. Animals were
euthanized by carbon dioxide inhalation. All efforts were made to
minimize suffering.

Mass Spectrometry Analysis
To detect JMJD3 interacting proteins, empty vector (p3xFLAGCMV, Sigma) and JMJD3-Flag were transfected into HEK293
cells using Lipofectamine 2000 (Invitrogen). 2 days following
transfection, cells were lysed with 1x RIPA lysis buffer (Pierce). Coimmunoprecipitation was performed on approximately 1mg of
protein from each sample using 10 mg of anti-flag antibody. The
protein complexes were analyzed on a 6% TBE non-denaturing
polyacrylamide gel with a PageRuler Plus pre-stained ladder
(Thermo scientific) as marker. Gels were fixed in 50% methanol/
distilled water and stained with coomassie blue (GelCode Blue
Stain, Pierce) at room temperature for 1 hour. The Coommassie
Blue stained gel bands underwent tryptic digestion to extract the
peptides for MS analysis [21]. Briefly, each digested peptide
sample was loaded on an Agilent 1200 nano-capillary HPLC
system (Agilent Technologies) with a 10 cm integrated mRPLCelectrospray ionization (ESI) emitter columns (made in-house),
coupled online with a LTQ XP mass spectrometer (Thermo Fisher
Scientific) for mRPLC-MS/MS analysis. Peptides were eluted
using a linear gradient of 2% mobile phase B (acetonitrile with
0.1% formiac acid) to 42% mobile phase B within 40 min at
a constant flow rate of 0.25 mL/min. The seven most intense
molecular ions in the MS scan were sequentially selected for
collision-induced dissociation (CID) using a normalized collision
energy of 35%. The mass spectra were acquired at the mass range
of m/z 350–1800. The ion source capillary voltage and
temperature were set at 1.7 kV and 200uC, respectively. The
MS/MS data were searched against p53 protein database using
SEQUEST. The cut-off for legitimate identifications were: charge
state dependent cross correlation (Xcorr) $2.0 for [M+H]1+, $2.5
for [M+2H]2+ and $3.0 for [M+3H]3+.
PLOS ONE | www.plosone.org

Results
JMJD3 is Induced during Differentiation of GSCs
It has been shown that retinoic acid (RA) induces partial cell
cycle arrest and differentiation of primary glioblastoma stem cells
(GSCs) thereby inhibiting their tumorigenic potential [14,23].
Consistent with these reports, RA promoted glial differentiation of
GSC 827 as demonstrated by induction of glial fibrillary acid
protein (GFAP) and astrocyte-like morphologic change (Figure 1A).
As seen in normal mouse neural stem cells (MsNSCs) [4], we find
that RA induces JMJD3 in GSCs but not in the long-established
U87MG glioma cell line (Figure 1B). This suggests that induction
of JMJD3 may not occur in more differentiated cell types but only
in cells with stem cell-like properties. We investigated this
possibility by comparing RA induction of JMJD3 in the CD15/
SSEA-1+ subpopulation of primary GSC 827 based on our prior
3
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report demonstrating that CD15/SSEA-1+ enriches for a population of tumor cells with stem cell-like properties [13]. We purified
CD15/SSEA-1+ and CD15/SSEA-12 from GSC 827 by magnetic activated cell sorting (MACS) (Table S1) and treated with
RA. RA induced JMJD3 and GFAP in the CD15/SSEA-1+
subpopulation, whereas RA did not cause induction of JMJD3 or
differentiation in the CD15/SSEA-12 population (Figure S1).
These data suggest that JMJD3 may be involved in the induction
of differentiation programs in tumor stem cells in much the same
way it activates such programs in normal stem cells.

JMJD3 Modulates Differentiation of GSCs Independently
of INK4A/ARF Locus
During oncogene-induced senescence, JMJD3 demethylates
H3K27me3 relieving repression of the INK4A/ARF promoter.
This results in p16/p14 expression, p53 protein stabilization and
p21 induction leading to senescence of human and mouse
fibroblasts [2,24]. In GSC 923 (wild-type INK4A/ARF, wild-type
TP53; Table S2), overexpression of wild-type JMJD3 (Intact
catalytic domain. Figure S2) induced GFAP expression, while
mutant JMJD3 (MT; Deleted catalytic domain. Figure S2) did not
(Figure 1C). JMJD3 also significantly inhibited proliferation of
GSC 923 consistent with its pro-differentiation effects (Figure 1D).
Surprisingly, JMJD3 overexpression in INK4A/ARF null (but wild-

Figure 1. JMJD3 is induced during differentiation of GSCs. A, Immunofluorescence of glioblastoma stem cells 827 (GSC 827) showing
expression of mature astrocyte marker glial fibrillary acid protein (GFAP, in red) in proliferative media consisting of epidermal growth factor (EGF) and
fibroblast growth factor (FGF) (i–iii) and differentiation media with 2 mM all-trans retinoic acid (RA) (iv–vi). DAPI (blue) depicts nuclei. Scale bar
represents 20 mm. B, Quantitative real-time PCR (RT-qPCR) showing effect of retinoic acid (RA) on JMJD3 transcriptional activity during differentiation
of mouse neural stem cells (MsNSC), glioblastoma stem cells (GSCs) and serum grown U87 malignant glioblastoma cell line (U87MG). C, RT-qPCR on
GSC 923 (wild-type INK4A/ARF, wild-type TP53) showing the effect of wild-type JMJD3 and mutant JMJD3 (MT) overexpression on GFAP expression. D,
Effect of JMJD3 and JMJD3 MT overexpression on proliferation of GSC 923. E–F, The effect of JMJD3 overexpression (E; Luciferase assay) and
knockdown on GFAP promoter activity (F; RT-qPCR) in GSC 1228 (INK4A/ARF null and wild type TP53). All experiments were done in triplicates.
Error bars represent means 6SD. p = two-tailed Student’s t test comparing indicated samples, *p,0.1, **p,0.05, ***p,0.01, N.S.- not significant.
doi:10.1371/journal.pone.0051407.g001
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type TP53) GSC 1228 also induced GFAP promoter activity
(Figure 1E), while siRNA-mediated knockdown of JMJD3
inhibited GFAP promoter activity (Figure 1F). These results
suggest that JMJD3 may modulate differentiation of GSCs
independently of its reported cell cycle associated chromatin
target, INK4A/ARF.
In wild-type INK4A/ARF and wild-type TP53 GSC 923, JMJD3
induced p16/p14 and p21 mRNA expression (Figure 2A) consistent with re-activation of the INK4A/ARF locus via chromatin
remodeling as shown in other cell types6,7. In INK4A/ARF null
GSC 1228 and wild-type INK4A/ARF HEK 293 cells (both with
wild-type TP53), however, JMJD3 also induced p21 mRNA but
without p16/p14 or p53 induction (Figure 2B, C) suggesting that
JMJD3 mediated p21 induction in these cell types may be
independent of both INK4A/ARF and TP53 transcriptional
activation. We also find that p21 is induced during RA and serum
mediated differentiation of GSCs (Figure S3), while exogenous p21
overexpression in GSCs is associated with GFAP expression (Figure
S3). Moreover, JMJD3 mediated p21 protein expression is
associated with GFAP protein induction in GSCs only
(Figure 2D). Therefore, our results suggest that induction of
JMJD3 during differentiation of GSCs may promote cell cycle
arrest and partial glial differentiation through p21 activation,
independently of INK4A/ARF or TP53 transcriptional control.

JMJD3 Induction of p21 is p53-dependent
We next investigated how JMJD3 could activate p21 independently of transcriptional up-regulation of p14 (ARF) or p53
(TP53). JMJD3 overexpression in HEK 293 cells did not affect
total p53 levels (consistent with a lack of INK4A/ARF or TP53
transcriptional activation) but promoted its nuclear accumulation
(Figure 3A, B). ChIP analysis of the endogenous human p21
promoter (Figure 3C) shows that JMJD3 overexpression results in
accumulation of RNA polymerase II (Figure 3D) and p53
(Figure 3E), but not JMJD3 at the p21 promoter (Figure 3F).
Moreover, mutation of the p53 binding site on an episomal nonchromatin based human p21 promoter luciferase reporter significantly diminished p21 promoter activation by JMJD3 in HEK
293, mouse neural stem cells and GSC 923 (Figure 4A–D). These
data indicate that increased p53 nuclear localization and subsequent accumulation at the p21 promoter mediates chromatin
independent JMJD3 induction of p21.
We then explored a potential non-chromatin modifying
mechanism responsible for JMJD3-mediated p53 pathway activation. Recent evidence suggests that histone lysine modifiers may
target non-histone substrates. For example, histone methyltransferases G9a, SET7 and SET9 induce the methylation of many
non-histone substrates [25] including p53. Additionally, the
H3K4me3 demethylase LSD1 was shown to demethylate lysine
370 on the p53 c-terminus, resulting in repression of p53 stability
and function [26]. Co-immunoprecipitation experiments demonstrate that JMJD3 interacts with endogenous p53 in both HEK

Figure 2. JMJD3 induces p21 in GSCs. A–C, Effect of JMJD3 overexpression on p16/p14, p53 and p21 mRNA expression in GSC 923 (wild-type
INK4A/ARF and TP53) (A) and GSC 1228 ( INK4A/ARF null, wild-type TP53) (B) and HEK 293 cells (wild-type INK4A/ARF and TP53) (C). D, Western blot
analysis showing the effect of JMJD3 on p21 and GFAP protein expression in primary GSCs and HEK 293 cells. All experiments were done in triplicates.
Error bars represent means 6SD. p = two-tailed Student’s t test comparing indicated samples to empty vector control, *p,0.1, **p,0.05, ***p,0.01,
N.S.-not significant.
doi:10.1371/journal.pone.0051407.g002
‘‘
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Figure 3. JMJD3 induction of p21 is p53-dependent. A, Western blot analysis showing the effect of JMJD3 overexpression on total p53 levels in
HEK 293 cells. B, Nuclear fractionation following JMJD3 overexpression in HEK 293 cells (N-Nuclear fraction, C-Cytoplasmic fraction). Total Histone 3
(Total H3) was used as nuclear loading control and Tubulin as cytoplasm loading control. Densitometry values of p53 expression (black) are relative to
respective nuclear or cytoplasmic control. C, Schema of human p21 promoter showing p53 consensus binding sites and primers used for Chromatin
immunoprecipitation with PCR (ChIP-PCR). TSS is transcription start site, 39 and 59 sites represent consensus p53 binding sites within the human p21
promoter. D–F, ChIP-PCR results showing localization of RNA polymerase II (D), p53 (E) and JMJD3 (F) at the p21 promoter in HEK 293 cells following
JMJD3 overexpression. All experiments were done in triplicates. Error bars represent means 6SD. p = two-tailed Student’s t test comparing indicated
samples to empty vector controls, *p,0.1, **p,0.05, ***p,0.01, N.S.- not significant.
doi:10.1371/journal.pone.0051407.g003

active form of p53 previously shown to mediate p21 activation
[28]. Here, we find that JMJD3 overexpression promoted nuclear
retention of a p53K372me1, more than doubling the ratio of
nuclear to cytoplasmic p53K372me1 (Figure 5D). Given that our
MS experiments did not provide direct evidence of active p53
demethylation, the mechanism for enhanced nuclear localization
of p53K372me1 remains unresolved. Therefore, we propose that
p53 lysine 372 demethylation may be one of several mechanisms
contributing to p53 nuclear retention during JMJD3-mediated
differentiation of glioblastoma stem cells.

293 (Figure 5A) and GSC 923 (Figure 5B; confirmed by liquid
chromatography/mass spectrometry (LC/MS); Figure 5C). Further studies revealed that the c-terminal jumonji domain (JmjC) of
JMJD3 is required for this interaction as a JmjC-deletion mutant
JMJD3 does not interact with p53. Given its role as a histone lysine
demethylase, we asked if JMJD3 induces p21 via direct lysine
demethylation of p53. A previous publication demonstrated that
the interaction between JMJD3 and p53 results in demethylation
of lysine residues on p53 [27]. Specific lysine residues, however,
were not assessed or characterized as potential JMJD3 targets on
p53. Thus, given the impact of JMJD3 over-expression on
differentiation in INK4A/ARF null but wild-type TP53 GSCs, we
sought to characterize specific lysine targets of JMJD3 on p53 via
methylation profiling with mass spectrometry (MS). MS, however,
was unable to detect baseline methylation on p53 protein in
control samples. Next, we increased protein amounts as well as
enriched for p53 protein from nuclear and cytoplasmic extracts
through immunoprecipitation, however, baseline methylation on
p53 protein could not be established. We were, therefore, unable
to confirm or repudiate previous published evidence of lysine
demethylation following JMJD3-p53 interaction [27].
Given a global decrease in lysine methylation on p53 following
JMJD3 interaction [27], we looked for putative methylated lysines
on p53, that following modification not only promote the stability
of p53 but also activate the p21 promoter. It was previously
reported that mono-methyl p53 lysine 372 (p53K372me1) is an
PLOS ONE | www.plosone.org

JMJD3 (KDM6B) Locus Harbor Aberrations in GBM
To assess the potential relevance of JMJD3 in human
gliomagenesis, we looked for naturally occurring alterations within
the JMJD3 locus that could affect JMJD3 activity or expression in
GBMs. First, we queried whole exome sequence data from The
Cancer Genome Atlas (TCGA) [29] as well as sequence data from
primary GSCs derived in the Neuro-Oncology Branch at the
National Institutes of Health. We found at least 3 different
missense mutations and insertions within the TCGA database,
(Table S3). Likewise, 3 of our 5 whole exome sequenced GSCs:
GSC 308, GSC 1228 and GSC 827, also harbor missense
mutations within the JMJD3 locus (Table S3).
To look for epigenetic changes in primary GBMs that could
affect JMJD3 expression and function, whole genome DNA
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Figure 4. Effect of JMJD3 on the human p21 promoter. A–D, Effect of JMJD3 overexpression on human p21 promoter luciferase reporter (A) in
HEK 293 (B), mouse neural stem cells E14 (MsNSCs) (C) and GSC 923 (D) with a wild-type p53 59 binding site (wild-type 59 site) and mutant p53 59
binding site (mutant 59 site; Position 2279 C.A in red (A)). TSS is transcription start site, 39 and 59 sites represent consensus p53 binding sites within
the human p21 promoter. All experiments were done in triplicates. Error bars represent means 6SD. p = two-tailed Student’s t test comparing
indicated samples, *p,0.1, **p,0.05, ***p,0.01, N.S.-not significant.
doi:10.1371/journal.pone.0051407.g004

(Figure 6A; red arrow). JMJD3 expression is also relatively
suppressed in GBM 827-P compared to non-tumor brain and
other tumors GBM 206-P and GBM 923-P (Figure S4) while
western blot analysis showed lower JMJD3 protein expression in
GSC 827 compared to other GSCs (Figure S4). These results
suggest that methylation of the JMJD3 regulatory element may
affect JMJD3 expression in GBM 827.

methylation arrays were performed on a series of parental
glioblastoma samples (GBM-P, n = 7) which demonstrated that
compared to non-tumor brain tissue, all GBM samples show
relative hypermethylation of a CpG site (Illumina cg09911083)
within the JMJD3 intragenic regulatory element (Figure 6A;
Chr.17p13.1:7,695,644–7,696,309; UCSC NCBI36/Hg18[30–
32]). By contrast, the JMJD3 promoter shows no significant
hypermethylation in non-tumor brain tissue (Figure 6A). For
example, primary GBM 827 (GBM 827-P) demonstrates highly
significant levels of methylation at the JMJD3 regulatory element
relative to non-tumor brain tissue and other tumor samples

Figure 5. JMJD3 stabilizes p53 protein. A–B, Co-immunoprecipitation in HEK 293 cells (A) and GSC 923 (B) following overexpression of wildtype JMJD3 (in-tact catalytic domain) and mutant JMJD3 (MT; deleted catalytic domain) and western blot analysis for endogenous p53 protein. IP,
immunoprecipitation. C, Mass spectrometry on JMJD3 interacting proteins in HEK 293 cells. D, Effect of JMJD3 overexpression on the cellular
distribution of mono-methylated p53 lysine 372 (p53K372me1). N-Nuclear fraction and C-Cytoplasmic fraction. Total Histone 3 (Total H3) was used as
nuclear fraction control and Tubulin as cytoplasmic fraction control. Densitometry values of p53K372me1 (white) are relative to respective nuclear or
cytoplasmic control.
doi:10.1371/journal.pone.0051407.g005
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Figure 6. Regulatory element DNA demethylation re-activates JMJD3 mRNA in GSC 827. A, Illumina Infinium Human Methylation 450 bead
chip methylation arrays on parental GBM tumor samples (GBM-P) compared to non-tumor brain tissue (Non-tumor brain 44-69-20-3) showing the
methylation status (0%-unmethylated, 100%-hypermethylated) of JMJD3 regulatory regions (Chromosome 17. UCSC NCBI 36/Hg 18). B, (Top) Heat
map from whole genome DNA methylation profiling showing that 5-Azacytidine reproducibly demethylates the JMJD3 regulatory element (from 2
independent experiments). (Bottom) Bisulfite sequencing confirmed JMJD3 regulatory element in GSC 827 demethylation following 5-Azacytidine
treatment. No significant changes were found at the promoter. X indicates cg09911083. C–D, Effect of 5-Azacytidine on JMJD3 mRNA (C) expression
as well as differentiation markers b-TUBULIN III (TuJ1) (D) in GSC 827. JMJD3 SMARTpool siRNA knockdown inhibits 5-Azacytidine induced
differentiation of GSC 827. E–F, Immunocytochemistry of GSC 827 showing the effects of JMJD3 knockdown on p53 nuclear accumulation before (E)
and after (F) 5-Azacytidine treatment as assessed by morphology and b-TUBULIN III expression. Arrows pointing to differentiated GSCs with nuclear
p53. Scale bar represents 20 mm. All experiments were done in triplicates. Error bars represent means 6SD. p = two-tailed Student’s t test comparing
indicated samples to EGF+FGF control, *p,0.1, **p,0.05, ***p,0.01, N.S.- not significant.
doi:10.1371/journal.pone.0051407.g006

and the retinoic acid receptor RXR-A[4,30–33]. Therefore, to
determine if hypermethylation of this intragenic JMJD3 enhancerlike region, is a regulatory mechanism contributing to suppression
of JMJD3 expression in gliomas such as GBM 827-P, we treated
GSC 827 with 5-Azacytidine and confirmed JMJD3 regulatory
element (but not promoter) demethylation through bisulfite
sequencing (Figure 6B). Regulatory element demethylation reactivates JMJD3 mRNA expression (Figure 6C) and induces
differentiation markers b-TUBULIN III (Figure 6D) and GFAP
(Figure S5) in GSC 827. Furthermore, siRNA mediated knockdown of JMJD3 following DNA demethylation in GSC 827
inhibited this differentiation (Figure 6D, Figure S5 and Figure S6
for protein knockdown confirmation). These results suggest that
DNA hypermethylation of the JMJD3 regulatory element
negatively regulates JMJD3 transcription and differentiation of
GSC 827.

JMJD3 Re-activation Induces a p53-mediated
Differentiation of GSCs
The publically available UCSC genome browser contains ChiPsequencing data and whole genome methylation profiles from
several cell lines including embryonic stem cells and cancer cell
lines. [30–33]. By analyzing data within the UCSC browser
genome browser, we found that cg019911083 is part of a CpG
island (Chromosome 17p13.1:7,695,644–7,696,309. UCSC
NCBI36/Hg18) previously annotated as a ‘positive regulatory
element’ [34,35] (Open Regulatory Annotation OREG0024145.
Chromosome 17p13.1:7,695,692–7,696,642. UCSC NCBI36/
Hg18)[30–33]. This region also demonstrates enhancer-like
features based on published regulatory element properties
[30,36] such as evolutionary conservation, DNase hypersensitivity,
enhancer-promoter associated histone mark (H3K4me1), RNA
polymerase II occupancy and binding by transcription factors (TF)
reported to activate JMJD3 expression such as NF-kB [3,30–33]
PLOS ONE | www.plosone.org
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had GSCs that were temporally and developmentally fixed in
a pro-proliferative, non-differentiated state through epigenetic
silencing of the bone morphogenic protein receptor 1b [20]. More
recently, it was demonstrated that IDH1 mutations promoted
aberrant histone demethylase activity resulting in a histone
methylation (H3K9me3 and H3K27me3) mediated block to
differentiation [1,16]. This was in part due to the inhibition of
a-ketoglutarate (a-KG) dependent enzymes such as the H3K9me3
demethylase, KDM4C. Amongst the many unresolved questions,
however, is the relevance of H3K27me3 demethylases in GBMs
and cancer in general.
In normal neural stem cells, the H3K27 specific demethylase
JMJD3 was shown to modulate differentiation by affecting p53
nuclear distribution [27]. The implications of these findings in any
cancer model, however, remains unclear. Here, we reveal that the
H3K27-specific demethylase, JMJD3, promotes differentiation
and suppresses proliferation of GSCs, not only through its wellknown chromatin-dependent activation of the INK4A/ARF locus,
but also through p53 protein nuclear stabilization. Based on
previous studies demonstrating global lysine demethylation on p53
following interaction with JMJD3 in differentiating neural stem
cells [27], our results suggest that lysine 372 modifications may
represent one of many putative mechanisms resulting in p53
protein stabilization following interaction with JMJD3 resulting in
differentiation and suppression of proliferation in glioblastoma
stem cells. We also demonstrate that primary-patient-derived
GSCs and primary human GBMs counter the tumor suppressor
effects of JMJD3 through hypermethylation of an evolutionarily
conserved intragenic and enhancer-like DNA regulatory element
within the JMJD3 locus or direct somatic mutations of the JMJD3
gene. Pharmacological demethylation of GSC with hypermethylation-silenced JMJD3 or overexpression of a wildtype JMJD3 in
JMJD3 mutated GSCs results in p53 pathway activation and GSC
differentiation in vitro and hugely extended survival of animals with
intracranial GSC xenografts. The clinical relevance of these
findings is reflected by our demonstration through genome wide
transcriptional motif analyses in a large number of GBM patients
that GBMs with high levels of JMJD3 expression and wildtype
TP53 show significantly enhanced p53 pathway activation.
Furthermore, our findings describe an alternative mechanism
(apart from 2-HG and a-KG) for how a DNA hypermethylation
phenotype in tumors like GBMs may functionally modulate the
activity/expression of the histone demethylases such as JMJD3 in
tumors like GBM 827. Moreover, we speculate that DNA
methylation may also affect JMJD3 mRNA processing via
transcription independent mechanisms (no impact on total mRNA
expression levels). It was demonstrated that intragenic DNA
hypermethylation may regulate differential exon inclusion during
mRNA elongation [39]. Here, DNA methylation impairs CTCF
binding to exon 5 and its inclusion into full length CD45 mRNA.
The JMJD3 regulatory element spans exon 17, which encodes for
part of the JMJD3 catalytic domain called jumjonji C (JmjC;
Exons 14–17), a region previously shown to be absolutely required
for the demethylase activity of JMJD3 (22 exons) [40]. Whole
genome ChIP-sequence data from embryonic stem cells in the
UCSC genome browser online also show that CTCF binds the
JMJD3 regulatory element, [30–32]. Thus, it is possible that
intragenic DNA hypermethylation could also impair JMJD3
activity by modulating CTCF-mediated JmjC demethylase
domain inclusion into full length JMJD3 mRNA. Therefore,
apart from modulating the activity of methylation sensitive
enhancers (as in GSC 827), intragenic hypermethylation in some
GBMs could also contribute to suppression of JMJD3 enzymatic
activity resulting in an aberrant block to terminal differentiation. If

Next, we assessed if RA mediated JMJD3 induction in GBM
GSCs is regulatory element methylation-dependent. We find that
RA treatment of GBM 827 GSCs induces JMJD3 without changes
to the methylation status of the JMJD3 promoter or downstream
regulatory element (Data not shown) suggesting that RA induces
JMJD3 via a methylation independent mechanism. In normal
neural stem cells (NSCs), it was shown that the RA nuclear corepressor SMRT/NCOR-2 controls the differentiation of neural
stem cells into neurons [4] and astrocytes [11]. In GSC 827, we
find that RA mediated astrocytic differentiation is associated with
a decrease in nuclear SMRT/NCOR-2 protein, JMJD3 induction
and p53 nuclear accumulation (Figure S7). These findings suggest
that JMJD3 mediated p53 pathway activation may be suppressed
in GBMs via multiple mechanisms.
Wild-type JMJD3 over-expression has been previously shown to
promotes p53 nuclear accumulation in normal NSCs [27]. To
establish whether regulatory element mediated JMJD3 re-activation induces differentiation of GSCs via p53 protein activation,
independently of INK4A/ARF, we assessed p53 nuclear localization following 5-azacytidine treatment of INK4A/ARF null (but
wild-type TP53) GSC 827. 5-Azacytidine significantly induced p53
nuclear accumulation with morphological evidence of differentiation in GSC 827 (Figure 6E–F, Figure S8). SiRNA mediated
knockdown of JMJD3 following 5-azacytidine treatment of GSC
827, however, significantly inhibited p53 nuclear accumulation
and morphologic evidence of differentiation (Figure 6F and Figure
S8). These results demonstrate that JMJD3 mediates p53-induced
differentiation of GSCs independently of the INK4A/ARF locus.

Relevance of JMJD3 Expression in vivo
To determine if the above in vitro effects of JMJD3 on p53 have
any clinical relevance, we asked whether JMJD3 expression in
parental GBM samples with wild-type TP53 influences p53
activity within those samples. To investigate this hypothesis, we
examined upstream promoter regions (2450/+50 of the Transcription Start Site) of genes differentially expressed between GBM
TP53 WT samples with high JMJD3 expression versus low JMJD3
expression. Using the PSCAN motif enrichment algorithm, we
found that a consensus binding motif for p53 is significantly
enriched in these promoters (fdr , = .05) greater than would be
expected by chance. This set of differentially expressed genes
showed predominant repression of p53 target genes in high
JMJD3 expressing GBMs compared with low JMJD3 expressing
GBMs (Figure 7A). These data are consistent with previous reports
that demonstrate that following p53 activation as many as 80% of
p53 responsive genes are repressed rather than activated [37,38]
and suggest that the p53 pathway is more active in high JMJD3
expressing GBMs retaining wild-type TP53 than in GBMs with
wild-type TP53 but low JMJD3 expression. Consistent with these
findings, mice with intracranial stereotactically injected JMJD3
over-expressing GSC 827 cells lived dramatically longer than mice
injected intracranially with parental GSC 827 cells (Figure 7B)
further demonstrating the tumor suppressive effects of JMJD3
in vivo.

Discussion
There is increasing evidence that a small subpopulation of cells
within human glioblastomas (GBMs) is instilled with tumorinitiating and neural stem cell properties (glioma stem cells, or
GSCs). The fact that GSCs can be driven toward terminal
differentiation in vitro, but rarely in vivo suggests, at least in part,
epigenetic regulation of differentiation. Consistent with this
supposition, we previously reported that a small subset of GBMs
PLOS ONE | www.plosone.org
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Figure 7. Relevance of JMJD3 expression in vivo. A, 672 differentially expressed p53 motif associated genes from TCGA GBM samples (wild-type
TP53) with high JMJD3 (Fold change .1.5; n = 7) and low JMJD3 (Fold change ,1; n = 18) expression. These genes contain a DNA motif in the -450/
+50 promoter region that scores 85% of total maximum possible for the p53 motif (TRANSFAC P53_02 motif). B, JMJD3 overexpression suppresses
tumorigenicity of GSC 827 in vivo (***Log Rank P = 0.0029).
doi:10.1371/journal.pone.0051407.g007

true, the aberrant methylation within the JMJD3 loci may prove
to be a useful therapeutic target in cancer.
Methylation independent mechanisms also exist for JMJD3
reactivation in GSCs. It has been shown that during neuronal
differentiation SMRT/NCOR-2 directly inhibits JMJD3 transcriptional activation by promoter-mediated repression, resulting
in a H3K27-mediated repression of differentiation genes [4]. RA
however, relieves this block by inducing the destabilization of
nuclear SMRT/NCOR-2 resulting in JMJD3 activation and

PLOS ONE | www.plosone.org

differentiation of NSCs [4]. SMRT/NCOR-2 has also been
previously shown to modulate the differentiation state and
tumorigenicity of GSCs [23,41]. Here, RA-mediated destabilization of nuclear SMRT/NCOR-2 [23] or serine/threonine protein
phosphatase 2A (PP2A)-mediated inhibition [41] results in
differentiation and suppresses proliferation of GSCs. Thus, JMJD3
may be re-activated in GSCs via methylation dependent and
independent mechanisms.
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Figure 8. Schematic model. Showing how JMJD3 activation of the p53 pathway in stem cells via chromatin and non-chromatin dependent
mechanisms contributes to differentiation. It also demonstrates that EZH2 over-expression as seen in some GBMs may promote self-renewal of stem
cells by suppressing the p53 pathway.
doi:10.1371/journal.pone.0051407.g008

Methylation and demethylation of p53 has been previously
shown to modulate p53 stability and function [26–28,42,43].
Others have demonstrated that the interplay between methylation
and acetylation of the p53 protein activates p53 during DNA
damage response [44]. Also, methylation of specific lysines has
been shown to affect the ability of p53 to interact with coactivators involved in p53-mediated apoptosis [26]. Therefore, it is
speculated that the interplay between methylation, demethylation
and acetylation may fine tune p53 activity during tumor initiation
and progression [45]. It remains largely unclear, however, how
methylation specifically stabilizes or destabilizes p53. To this end,
following our results showing the significant impact of a lysine
demethylase on p53 stability in cancer, it will be necessary to
perform methylation profiling on p53 to definitively establish
whether demethylases such as JMJD3 stabilize p53 through direct
demethylation and if not, through what other mechanisms.
In conclusion, the relevance of most histone demethylases,
including the H3K27me3 demethylase, JMJD3, in cancer remains
unclear. Here, we propose that JMJD3 acts as a tumor suppressor
gene in glioblastoma multiforme. We find that JMJD3 interacts
with p53 protein in GSCs and JMJD3 re-activation in GSCs
induces p53 nuclear accumulation in an INK4A/ARF null
background resulting in a p53-mediated differentiation of GSCs
(See model in figure 8). These findings point to a role for histone
demethylases in cancer and suggest that JMJD3 may serve as
a tumor suppressor gene and a potential therapeutic target in
glioblastoma multiforme.

PLOS ONE | www.plosone.org

Supporting Information
Retinoic acid induces JMJD3 in CD15+/SSEA-1+
subpopulation only. A, Retinoic acid induces JMJD3 in the
CD15+/SSEA-1+ GSC 827 stem cell subpopulation only. B,
Induction of JMJD3 in CD15+/SSEA-1+ GSC 827 is associated
with glial differentiation as measured by GFAP mRNA expression.
(JPG)
Figure S1

Figure S2 Wild-type JMJD3 demethylates H3K27me3. A–B,
Validation of wild-type JMJD3 (intact catalytic domain) ability to
demethylate H3K27me3 in HEK 293 cells (A). Mutant JMJD3
(MT; deleted catalytic domain) does not affect H3K27me3 levels
(B). Arrows showing cells of interest expressing either flag-tagged JMJD3 or
JMJD3 MT. Scale bar represents 20mm.
(JPG)
Figure S3 p21 contributes to differentiation of GSCs. A,
Quantitative real time PCR (RT-qPCR) showing the effect of
retinoic acid and serum on p21 expression in GSC 923. B–C, RTqPCR showing the effect of transient p21 overexpression (B) on
GFAP expression (C) in GSC 923.
(JPG)

JMJD3 expression in glioblastoma tumor samples. A,
Quantitative real-time PCR (RT-qPCR) showing relative levels of
JMJD3 mRNA in non-tumor brain tissue and parental GBM
samples (GBM-P). B, Western blot analysis showing JMJD3
protein expression across primary glioblastoma stem cells (GSCs).

Figure S4
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All experiments were done in triplicates. Error bars represent
means 6SD. p = two-tailed Student’s t test comparing indicated
samples to non-tumor brain tissue, *p,0.1, **p,0.05, ***p,0.01,
N.S.-not significant.
(JPG)

(JPG)
Table S1 Magnetic activated cell sorting of GSC 827. A, FACS

analysis on unsorted GSC 827 showing the prevalence of CD15+/
SSEA-1+ cells, the putative cancer stem cell population. B, FACS
analysis on sorted fractions of GSCs showing prevalence of each
sub-population following double sorting of GSC 827.
(JPG)

Figure S5 JMJD3 knockdown inhibits differentiation of GSC
827. Effect of 5-Azacytidine on GFAP mRNA expression with and
without JMJD3 knockdown. All experiments were done in
triplicates. Error bars represent means 6SD. p = two-tailed
Student’s t test comparing indicated samples, *p,0.1, **p,0.05,
***p,0.01, N.S., not significant.
(JPG)

Table S2 Characteristics of glioblastoma samples used in the
study. Showing genomic status of INK4A/ARF and TP53 loci of
glioblastoma samples used in the study.
(JPG)
Table S3 Whole exome sequence analysis from the JMJD3 locus
in human glioblastoma. Somatic mutations within the JMJD3
locus in glioblastoma (GBM) from the Cancer Genome Atlas
(TCGA) and the National Institutes of Health (NIH). SNV-Single
nucleotide variation, Het- Heterozygous, Hom-Homozygous.
(JPG)

Figure S6 Assessing JMJD3 siRNA knockdown efficiency in

GSC 827. Showing JMJD3 siRNA efficiently suppresses 5Azacytidine mediated JMJD3 protein induction in GSC 827.
EGF+FGF is control growth factor media.
(JPG)
Figure S7 NCoR2 mediates repression of JMJD3 expression in
GSC 827. Effect of RA on nuclear NCoR2 during differentiation
of GSC 827. NCoR2 destablization is associated with JMJD3
induction and p53 nuclear accumulation. N-Nuclear fraction and
C-Cytoplasmic fraction. Total Histone 3 (Total H3) was used as
nuclear fraction control and Tubulin as cytoplasmic fraction
control.
(JPG)
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